EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bod Science's Enterprise Value is A$3.19 Mil.
Bod Science's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 was A$0.94 Mil. Therefore, Bod Science's EV-to-FCF for today is 3.40.
The historical rank and industry rank for Bod Science's EV-to-FCF or its related term are showing as below:
ASX:BOD'
s EV-to-FCF Range Over the Past 10 Years
Min: -14.24 Med: -2.1 Max: 5.08
Current: 3.4
During the past 9 years, the highest EV-to-FCF of Bod Science was 5.08. The lowest was -14.24. And the median was -2.10.
ASX:BOD's EV-to-FCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 20.02
vs ASX:BOD: 3.40
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bod Science's PE Ratio (TTM) for today is calculated as:
Bod Science's share price for today is A$0.024.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bod Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was A$0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bod Science EV-to-FCF Related Terms
Bod Science EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bod Science's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bod Science's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bod Science EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bod Science's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bod Science's EV-to-FCF falls into.
Bod Science's current Enterprise Value is A$3.19 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bod Science's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 was A$0.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bod Science (ASX:BOD) has a EV-to-FCF of 3.40 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bod Science and its competitors.
Is Bod Science's EV-to-FCF too high?
Bod Science's current EV-to-FCF is 3.40. The Drug Manufacturers industry median EV-to-FCF is 20.02. Bod Science's value of 3.40 is 83% below this industry median. Overall, Bod Science has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bod Science's EV-to-FCF compare to ZTS?
Bod Science's EV-to-FCF of 3.40 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-FCF is 20.02. Bod Science's value of 3.40 is 83% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.02, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bod Science's current EV-to-FCF of 3.40 is 83% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bod Science and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bod Science's current EV-to-FCF is 3.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bod Science stock overvalued right now?
Bod Science (ASX:BOD) has a current EV-to-FCF of 3.40. The stock's GF Value™ is A$0.04, compared to a current price of A$0.02 — trading 40% below its estimated fair value. The current EV-to-FCF is 3.40 and 83% below the Drug Manufacturers industry median of 20.02. Bod Science's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bod Science (ASX:BOD), the current EV-to-FCF is 3.40 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bod Science (ASX:BOD) Overvalued in 2026?
Based on GuruFocus' analysis, Bod Science stock appears to be undervalued.
The current stock price of A$0.02 is trading 40% below its estimated GF Value™ of A$0.04.
Key valuation signals for ASX:BOD:
EV-to-FCF: 3.40
GF Value™: A$0.04 vs. price of A$0.02 (40% below fair value)
Industry Position: 83% below the Drug Manufacturers median
No single metric tells the full story. See the ASX:BOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bod Science Ltd is a healthcare company combining the power of nature and science to deliver cannabis-derived health and skincare products, designed to improve lives and transform the medicinal cannabis, CBD, and hemp market. The firm is focused on cannabis drug development and products. The company is focused on progressing Research and Development and a defined clinical trial pathway to commercialize and deliver premium, scientifically trusted products for the consumer and medical markets. It earned it profits and sales revenue from Australia even though have segment in UK, Europe and USA.
12GF Score
Get the complete analysis for ASX:BOD
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BOD has been successfully added to your 
